Scholar Rock Inc. CEO Nagesh Mahanthappa’s previous biopharma experiences include stints at RNAi powerhouse Alnylam Pharmaceuticals Inc. and privately held Avila Therapeutics Inc., which was snapped up by Celgene Corp. in a potential $935 million deal in 2012, and he is the first to admit that “those are high standards.”